Last reviewed · How we verify
AAV9 Gene therapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
AAV9 Gene therapy (AAV9 Gene therapy) — Celosia Therapeutics Pty Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AAV9 Gene therapy TARGET | AAV9 Gene therapy | Celosia Therapeutics Pty Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AAV9 Gene therapy CI watch — RSS
- AAV9 Gene therapy CI watch — Atom
- AAV9 Gene therapy CI watch — JSON
- AAV9 Gene therapy alone — RSS
Cite this brief
Drug Landscape (2026). AAV9 Gene therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/aav9-gene-therapy. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing